Panelists will explore the current state of cannabis legalization in various regions throughout the Americas and highlight emerging markets with high growth potential. Attendees will leave this panel with a deeper understanding of the current state and future potential of emerging cannabis markets in the Americas, as well as insights and strategies for success in these exciting and rapidly evolving markets.
Medical Cannabis: Overview of Emerging Legal Issues and their Impact on the International Market. The international panel of experts will notably discuss the differences in regulations between medical cannabis and pharmaceutical cannabis, how IP is becoming an essential topic with pharmaceutical cannabis medicines, and how it could also impact medical cannabis in the short run.
Interstate commerce continues to be at the forefront of the industry's collective mind as we look for solutions to incongruence of supply and demand, stalled equity programs, and fierce competition between and among both licensed participants and illicit businesses.
With a new Administration and Congress, changes in personnel at FDA and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50state?
In this 90-minute program, panelists will discuss a range of topics related to the interstate commerce ban, including licensee residency requirements adopted in many states (and associated litigation); the Dormant Commerce Clause; economic and social equity implications of closed markets; and the possibility of interstate compacts as a stopgap pending federal legalization. Speakers will also address the ban’s impact on medical patients and how pending legislation and post-legalization regulatory schemes may impact licensed operators and other industry participants.